This HTML5 document contains 134 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
n12http://dx.doi.org/10.1200/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n6http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q48693524
rdf:type
wikibase:Item
schema:description
artykuł naukowy article scientifique articol științific artigo científico 2011年學術文章 научни чланак artikel ilmiah vědecký článek wetenschappelijk artikel 2011年学术文章 vitenskapelig artikkel სამეცნიერო სტატია επιστημονικό άρθρο artículo científico publicado en 2011 vedecký článok научни чланак научная статья 2011年學術文章 videnskabelig artikel 2011年学术文章 мақолаи илмӣ artículu científicu 2011年学术文章 2011年学术文章 tieteellinen artikkeli 2011년 논문 wissenschaftlicher Artikel 2011 nî lūn-bûn مقالة علمية نشرت في 11 أبريل 2011 2011年學術文章 bilimsel makale scientific article published on 11 April 2011 artikulong pang-agham articolo scientifico bài báo khoa học บทความทางวิทยาศาสตร์ scientific article published on 11 April 2011 2011年学术文章 научна статия ১১ এপ্রিল ২০১১-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ teaduslik artikkel 2011年學術文章 artigo científico article scientific 2011年の論文 naučni članak 2011年學術文章 2011年学术文章 scienca artikolo vitskapeleg artikkel מאמר מדעי scientific article published on 11 April 2011 наукова стаття, опублікована у квітні 2011 article científic artikull shkencor tudományos cikk vetenskaplig artikel 2011 թվականի ապրիլի 11-ին հրատարակված գիտական հոդված artigo científico
p:P577
wds:Q48693524-E4CF6097-66FD-4CD6-AA64-68DBF23EBBA6
wdt:P577
2011-04-11T00:00:00Z
p:P407
wds:Q48693524-D5329FCB-395A-41D5-95CB-6925B3BE85D7
wdt:P407
wd:Q1860
p:P2093
wds:Q48693524-E4EAEC78-5237-46B4-9E11-AC665AB250FD wds:Q48693524-DC67427F-A925-48FB-86A3-6423DDEAA763 wds:Q48693524-DB46094A-E97F-4CE8-9E97-9E6584F432B1 wds:Q48693524-9910BF64-2DBF-4741-808A-FCAD8DB819E0 wds:Q48693524-7E239120-0D82-4239-95B4-A2D517C4BCFF wds:Q48693524-7FE81C5A-F4BB-455E-918C-392A2FE198F9 wds:Q48693524-71CD3563-DB78-4B21-93C4-64437F81A592 wds:Q48693524-62796AE5-8807-47AB-85F3-E57DADBB00BB wds:Q48693524-62DC18D3-B0BB-471E-95B2-DBF857815B50 wds:Q48693524-5F8EE69D-DEA9-447C-8E80-7FE872564096 wds:Q48693524-48FB9C4E-280F-4068-86E9-EDEA36BB2657 wds:Q48693524-43EBE513-28D0-402D-B794-35DA7B36CF2D wds:Q48693524-266F2E28-9A89-4C43-AC5D-54F9426FC3D6 wds:Q48693524-02A26C9B-9310-45B3-9336-2AFE6580D7C4
wdt:P2093
Filip Beeldens Pierre W Wijermans Helmut R Salih Karl-Heinz Pflüger Theo de Witte Boris Labar Corneel Coens Liliana Baila Anne Hagemeijer Björn Hans Rüter Arnold Ganser Hans Eckart Schaefer Michael Lübbert Dominik Selleslag
rdfs:label
Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation fo
skos:prefLabel
Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation fo Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome
schema:name
Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation fo
p:P50
wds:Q48693524-A013818A-5D15-481B-B640-BB24B3DBB088 wds:Q48693524-C8DD5B3C-4A98-42AA-9972-823C648356AF wds:Q48693524-D3921B8B-8EE0-46B4-A997-7D666B67523C wds:Q48693524-8A184EEE-8410-49D7-B089-0F6E0A8F5172 wds:Q48693524-3AA2D4BF-9EF3-4018-BC7E-23A1492F5B2F wds:Q48693524-16693D37-E913-4187-A1C6-2208A1612425
wdt:P50
wd:Q71792160 wd:Q71785823 wd:Q71785022 wd:Q99568574 wd:Q87993081 wd:Q71780112
p:P1476
wds:Q48693524-30C387C5-F20B-4890-8372-DF2A861FE92C
wdt:P1476
Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation fo
p:P304
wds:Q48693524-F2C138A7-E8D8-4752-A55B-55CAC7839F02
wdt:P304
1987-1996
p:P31
wds:Q48693524-3062EC9B-E98A-4C47-888B-E7F3E6ABA6E1
wdt:P31
wd:Q13442814
p:P921
wds:Q48693524-7A7B457C-9F1C-4897-B43C-5B2307F96965 wds:Q48693524-EDFA330D-67C0-4112-9891-8C117C0AA5D1 wds:Q48693524-246F992B-8AF5-4742-9EFE-99AF57CB7AB4
wdt:P921
wd:Q181600 wd:Q974135 wd:Q954625
p:P698
wds:Q48693524-F353813C-B767-4748-8B08-5C92F7CD6B81
wdtn:P698
n6:21483003
wdt:P698
21483003
p:P1433
wds:Q48693524-5251EEF6-9938-4FA4-A5A6-8FB8A2753C7B
wdt:P1433
wd:Q400292
p:P433
wds:Q48693524-C9439C60-FDCB-47B5-9009-B06B0E7C99C5
p:P478
wds:Q48693524-53DADAEA-9426-4778-BB81-6ED52757E047
wdt:P433
15
wdt:P478
29
p:P356
wds:Q48693524-260536E5-616E-401A-BDB6-4E1EC3F6E5C4
wdtn:P356
n12:JCO.2010.30.9245
wdt:P356
10.1200/JCO.2010.30.9245